SCHEMBL6464326

SCHEMBL6464326

O=C(NC(=O)c1cccc2ccccc12)c1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 1/20 0.66
HDAC8 Q9BY41 2/20 0.62
MMP3 P08254 1/20 0.62
ALDH1A1 P00352 4/20 0.62
HPGD P15428 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
NR4A1 P22736 1/20 0.58
NR4A2 P43354 1/20 0.58
NR4A3 Q92570 1/20 0.58
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
CYP1A2 P05177 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
KDM4E B2RXH2 2/20 0.56
HDAC3 O15379 1/20 0.54
HDAC4 P56524 1/20 0.54
HDAC1 Q13547 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1605906 0.91 HDAC8 (0.74) PLK1HDAC8MMP3ALDH1A1HPGD
SCHEMBL6633131 0.86 ALDH1A1 (0.82) PLK1HDAC8MMP3ALDH1A1HPGD
SCHEMBL3781509 0.85 MMP3 (0.67) PLK1HDAC8MMP3ALDH1A1HPGD
SCHEMBL28900406 0.85 HDAC8 (0.57) PLK1HDAC8MMP3ALDH1A1HPGD
SCHEMBL5427460 0.81 MMP3 (0.67) PLK1HDAC8MMP3ALDH1A1HPGD
SCHEMBL1563557 0.80 RAB9A (0.56) PLK1HDAC8MMP3ALDH1A1HPGD
SCHEMBL4307961 0.80 MMP3 (0.65) PLK1HDAC8MMP3ALDH1A1HPGD
SCHEMBL1794660 0.80 MMP3 (0.65) PLK1HDAC8MMP3ALDH1A1HPGD
SCHEMBL8505311 0.80 PLK1 (0.68) PLK1HDAC8MMP3ALDH1A1HPGD
SCHEMBL8191199 0.79 PLK1 (1.00) PLK1HDAC8MMP3ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101103002-A 3,4,(5)-substituted tetrahydropyridines NOVARTIS AG (CH) 2008-01-09 CN claimed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 PLK1 2105/4885HDAC8 4616/4885MMP3 4711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.